Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Advarra conducted a survey of sites, sponsors, and CROs that revealed three biggest barriers to stakeholder collaboration: communications, staffing, and technology.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

However, Vertex has a big opportunity and has over 50 authorized treatment centers activated. The company expects to share ...

Get Pro-Level Earnings Insights Before the Market Moves RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

In type 1 diabetes, zimislecel entered Phase 3 trials targeting 125,000 patients. Complementary therapies, including encapsulated islet cells in VX-264, are advancing, with pivotal data expected in ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

In December, Vertex's CASGEVY gained regulatory approval ... In type 1 diabetes, zimislecel entered Phase 3 trials targeting 125,000 patients. Complementary therapies, including encapsulated ...